MiMedx

MiMedx

Founded 2008

Marietta, United States 835 employees Grant Total: $266.36M Biotechnology, Health Care +3

MiMedx is a pioneering company in the biotechnology and healthcare industries, specializing in placental tissue products. Established in 2008 and headquartered in the United States, the company has been at the forefront of developing solutions for chronic and hard-to-heal wounds, with a commitment to enhancing the quality of life for patients. Its extensive experience spanning over a decade reflects its dedication to providing a leading portfolio of products for wound care, burn, and surgical applications within the healthcare sector. In its most recent funding round on 31 May 2022, MiMedx secured a significant investment of $4.60M from the Medical Technology Enterprise Consortium. This injection of capital underscores the confidence of industry investors in the company's vision. It is evident that the support from such a reputable investor further strengthens MiMedx's position and aids in its relentless pursuit of innovation to deliver healing solutions to a global market. MiMedx's focus on innovation and its ability to attract investments from leading industry players positions the company as a key player in the healthcare sector. With a clear vision to be the leading global provider of healing solutions, MiMedx is well-equipped to continue driving advancements in the field of placental tissue and furthering its impact on patient care and outcomes.

Funding Stage	Amount	Investors	Lead Investors	Date
Grant	$4.60M	1	Medical Technology Enterprise Consortium	31 May 2022
Post IPO Debt	$50.00M	1	Hayfin Capital Management	02 Jul 2020
Post IPO Equity	$100.00M	1	Essex Woodlands Healthcare Partners	02 Jul 2020
Post IPO Debt	$75.00M	-		12 Jun 2019
Post IPO Equity	$34.00M	-		18 Dec 2013
Post IPO Equity	$2.08M	-		30 Nov 2010
Post IPO Equity	$675.00K	-		30 Oct 2009

Funding Stage

Amount

Investors

Lead Investors

Date

Grant

$4.60M

Medical Technology Enterprise Consortium

31 May 2022

Post IPO Debt

$50.00M

Hayfin Capital Management

02 Jul 2020

Post IPO Equity

$100.00M

Essex Woodlands Healthcare Partners

02 Jul 2020

Post IPO Debt

$75.00M

12 Jun 2019

Post IPO Equity

$34.00M

18 Dec 2013

Post IPO Equity

$2.08M

30 Nov 2010

Post IPO Equity

$675.00K

30 Oct 2009

FAQ About MiMedx

MIMEDX is a pioneer and leader in the field of placental tissue. With more than a decade of helping clinicians manage chronic and hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical settings of healthcare. The C...

MiMedx was founded in 2008.

MiMedx is headquartered in Marietta, United States.

MiMedx operates in Biotechnology, Health Care, Health and Wellness, Medical Devices and Marketing. Its work centres on Advanced wound care, Therapeutic biologics, Human placental tissue allografts and Patent-protected processes.

MiMedx has approximately 835 employees.

MiMedx has completed 7 funding rounds, raising a total of $266.36M. The latest funding stage is Grant.

Top alternatives and competitors to MiMedx include Stability Biologics, Colzyx, OxyBand Technologies, Inc., Ivivi Technologies, SANUWAVE. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

MiMedx and Stability Biologics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About MiMedx

Funding Rounds & Investors (7)

MiMedx Alternatives & Competitors

FAQ About MiMedx